We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

876 hedge funds and large institutions have $40B invested in Teva Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 290 increasing their positions, 310 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 69

79% more call options, than puts

Call options by funds: $1.18B | Put options by funds: $662M

50% more funds holding in top 10

Funds holding in top 10: 58 → 87 (+29)

34% more capital invested

Capital invested by funds: $29.9B → $40B (+$10.1B)

6% more funds holding

Funds holding: 823 → 876 (+53)

4.84% more ownership

Funds ownership: 55.28% → 60.12% (+4.8%)

6% less repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 310

Holders
876
Holders Change
+53
Holders Change %
+6.44%
% of All Funds
22.98%
Holding in Top 10
87
Holding in Top 10 Change
+29
Holding in Top 10 Change %
+50%
% of All Funds
2.28%
New
135
Increased
290
Reduced
310
Closed
69
Calls
$1.18B
Puts
$662M
Net Calls
+$522M
Net Calls Change
+$500M

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$999M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$771M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$474M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$372M
5
IC
Institutional Capital
Illinois
+$270M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$430M
2
MIP
Mondrian Investment Partners
United Kingdom
-$244M
3
Renaissance Technologies
Renaissance Technologies
New York
-$145M
4
NTC
North Tide Capital
Massachusetts
-$105M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$99.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
51
Acadian Asset Management
Massachusetts
$179M -$90.7M -1,467,613 -35%
O
52
OppenheimerFunds
New York
$176M -$15.2M -245,716 -8%
Deutsche Bank
53
Deutsche Bank
Germany
$168M +$10.3M +166,054 +7%
American Century Companies
54
American Century Companies
Missouri
$168M +$50.7M +819,677 +47%
Ameriprise
55
Ameriprise
Minnesota
$163M +$14.5M +234,209 +10%
O
56
OrbiMed
New York
$161M +$15.3M +247,000 +11%
UBS AM
57
UBS AM
Illinois
$157M +$36M +583,167 +32%
Macquarie Group
58
Macquarie Group
Australia
$132M -$91.3M -1,476,924 -42%
Wells Fargo
59
Wells Fargo
California
$129M -$6.16M -99,606 -5%
BM
60
Bridger Management
New York
$124M -$1.39M -22,509 -1%
TSW
61
Thompson Siegel & Walmsley
Virginia
$123M +$22.4M +362,150 +24%
PHS
62
PFM Health Sciences
California
$122M +$19.9M +322,087 +21%
Jennison Associates
63
Jennison Associates
New York
$118M -$6.46M -104,505 -5%
PCM
64
Polaris Capital Management
Massachusetts
$118M +$5.55M +89,828 +5%
CCM
65
Camber Capital Management
Massachusetts
$118M -$12.4M -200,000 -10%
Principal Financial Group
66
Principal Financial Group
Iowa
$118M +$10.3M +166,879 +10%
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$118M -$535K -8,664 -0.5%
TD Asset Management
68
TD Asset Management
Ontario, Canada
$117M +$38M +615,081 +52%
PNC Financial Services Group
69
PNC Financial Services Group
Pennsylvania
$113M +$10.9M +175,900 +11%
EARNEST Partners
70
EARNEST Partners
Georgia
$108M +$3.46M +55,976 +4%
SC
71
Samlyn Capital
New York
$108M -$54.5M -882,487 -35%
TCIM
72
TIAA CREF Investment Management
New York
$108M +$71.9M +1,163,133 +243%
Morgan Stanley
73
Morgan Stanley
New York
$106M +$966K +15,631 +1%
AI
74
Axiom Investors
Connecticut
$102M -$23.3M -376,969 -19%
AIM
75
Assured Investment Management
New York
$99.9M +$94.1M +1,522,545 New
1 2
3
4 5

TEVA Hedge Fund Activity: Q4 2015 in Review

876 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2015, worth a combined $40B — up 34% from $29.9B a quarter earlier.

Buyers outnumbered sellers: 135 funds opened new TEVA positions and 69 closed out — a net gain of 66 holders — while 290 added to existing stakes and 310 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $999M. The largest seller was Franklin Resources, cutting an estimated $430M.

  • 876 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2015, up from 823 in Q3 2015.
  • Funds reported $40B of Teva Pharmaceuticals stock for Q4 2015, up 34% quarter-over-quarter.
  • 135 funds opened new Teva Pharmaceuticals positions in Q4 2015 and 69 closed out, a net change of +66 holders.
  • The largest Teva Pharmaceuticals buyer in Q4 2015 was Viking Global Investors, an estimated $999M added.
  • The largest Teva Pharmaceuticals seller in Q4 2015 was Franklin Resources, an estimated $430M sold.

Based on aggregated 13F filings for Q4 2015.